MediWound Ltd. develops and commercializes enzymatic, non-surgical therapies for tissue repair as a global biotechnology company. Its FDA-approved biologic NexoBrid is indicated for enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and other international markets.
News about MDWD commonly covers financial results, corporate updates, NexoBrid commercialization and distribution, BARDA-supported burn-care activity, and the development of EscharEx, an investigational bromelain-based therapy for debridement of chronic and hard-to-heal wounds. Company updates also include clinical data presentations, wound-care conference activity, regulatory filings, and shareholder communications.
MediWound Ltd. (Nasdaq: MDWD) reported its Q1 2020 financial results with total revenues of $4.4 million, a significant increase from $0.5 million in Q1 2019. The operating loss narrowed to $2.2 million from $3.6 million year-over-year. Operating cash flow was $2.1 million, and the company held $27.3 million in cash and short-term investments, carrying no debt. MediWound resumed clinical trials for EscharEx treatment and expanded its contract with BARDA for NexoBrid, reflecting ongoing operational stability amidst the COVID-19 pandemic.
MediWound Ltd. (Nasdaq: MDWD) will release its financial results for Q1 2020 on May 20, 2020, at 7:00 am ET. Following this, a conference call will be held at 8:30 am ET to discuss the results. Participants can join via toll-free numbers or through the provided webcast link. MediWound focuses on developing innovative therapies for severe burns and hard-to-heal wounds. Its renowned products include NexoBrid and EscharEx, utilizing patented proteolytic enzyme technology.
Summary not available.
Summary not available.